Top

Cancer and Metastasis Reviews

Published in:

Open Access 01-03-2022 | Neuroblastoma | Non-Thematic Review

Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology

Authors: Esteban Javier Rozen, Jason Matthew Shohet

Published in: Cancer and Metastasis Reviews | Issue 1/2022

Abstract

Background

Neuroblastoma is a devastating disease accounting for 15% of all childhood cancer deaths. Yet, our understanding of key molecular drivers such as receptor tyrosine kinases (RTKs) in this pathology remains poorly clarified. Here, we provide a systematic analysis of the RTK superfamily in the context of neuroblastoma pathogenesis.

Methods

Statistical correlations for all RTK family members’ expression to neuroblastoma patient survival across 10 independent patient cohorts were annotated, synthesized, and ranked using the R2: Genomics Analysis and Visualization Platform. Gene expression of selected members across different cancer cell lines was further analyzed in the Cancer Cell Line Encyclopedia, part of the Cancer Dependency Map portal (depmap portal (http://depmap.org)). Finally, we provide a detailed literature review for highly ranked candidates.

Results

Our analysis defined two subsets of RTKs showing robust associations with either better or worse survival, constituting potential novel players in neuroblastoma pathophysiology, diagnosis, and therapy. We review the available literature regarding the oncogenic functions of these RTKs, their roles in neuroblastoma pathophysiology, and potential utility as therapeutic targets.

Conclusions

Our systematic analysis and review of the RTK superfamily in neuroblastoma pathogenesis provides a new resource to guide the research community towards focused efforts investigating signaling pathways that contribute to neuroblastoma tumor establishment, growth, and/or aggressiveness and targeting these druggable molecules in novel therapeutic strategies.

Available only for authorised users

Blume-Jensen, P., & Hunter, T. (2001). Oncogenic kinase signalling. Nature, 411(6835). https://doi.org/10.1038/35077225

Ullrich, A., & Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell. https://doi.org/10.1016/0092-8674(90)90801-KCrossRefPubMed

Schlessinger, J. (2000, October 13). Cell signaling by receptor tyrosine kinases. Cell. Cell Press. https://doi.org/10.1016/S0092-8674(00)00114-8

Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 1117–1134. https://doi.org/10.1016/j.cell.2010.06.011CrossRefPubMedPubMedCentral

Bousoik, E., & Montazeri Aliabadi, H. (2018). “Do we know jack” about JAK? A closer look at JAK/STAT signaling pathway. Frontiers in Oncology. https://doi.org/10.3389/fonc.2018.00287

Roy, J. P., Halford, M. M., & Stacker, S. A. (2018). The biochemistry, signalling and disease relevance of RYK and other WNT-binding receptor tyrosine kinases. Growth Factors, 36(1–2), 15–40. https://doi.org/10.1080/08977194.2018.1472089CrossRefPubMed

Louis, C. U., & Shohet, J. M. (2015). Neuroblastoma: Molecular pathogenesis and therapy. Annual Review of Medicine, 66, 49–63. https://doi.org/10.1146/annurev-med-011514-023121CrossRefPubMed

Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., … Maris, J. M. (2013). The genetic landscape of high-risk neuroblastoma. Nature Genetics, 45(3). https://doi.org/10.1038/ng.2529

Fujita, T., Igarashi, J., Okawa, E. R., Gotoh, T., Manne, J., Kolla, V., … Brodeur, G. M. (2008). CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. Journal of the National Cancer Institute, 100(13). https://doi.org/10.1093/jnci/djn176

10.

Theissen, J., Oberthuer, A., Hombach, A., Volland, R., Hertwig, F., Fischer, M., … Berthold, F. (2014). Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma. Genes Chromosomes and Cancer, 53(8). https://doi.org/10.1002/gcc.22174

11.

Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., … Maris, J. M. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 455(7215). https://doi.org/10.1038/nature07261

12.

Minuti, G., D’Incecco, A., Landi, L., & Cappuzzo, F. (2014). Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 15(9). https://doi.org/10.1517/14656566.2014.909412

13.

ULIVI, P., ZOLI, W., CAPELLI, L., CHIADINI, E., CALISTRI, D., & AMADORI, D. (2013). Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. Molecular and Clinical Oncology, 1(4). https://doi.org/10.3892/mco.2013.100

14.

Reiff, T., Huber, L., Kramer, M., Delattre, O., Janoueix-Lerosey, I., & Rohrer, H. (2011). Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development, 138(21). https://doi.org/10.1242/dev.072157

15.

Wang, M., Zhou, C., Sun, Q., Cai, R., Li, Y., Wang, D., & Gong, L. (2013). ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Experimental and Molecular Pathology, 95(2). https://doi.org/10.1016/j.yexmp.2013.06.002

16.

Agarwal, S., Lakoma, A., Chen, Z., Hicks, J., Metelitsa, L. S., Kim, E. S., & Shohet, J. M. (2015). G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation. Cancer Research, 75(12), 2566–2579. https://doi.org/10.1158/0008-5472.CAN-14-2946CrossRefPubMedPubMedCentral

17.

Schulte, J. H., Lindner, S., Bohrer, A., Maurer, J., De Preter, K., Lefever, S., … Schramm, A. (2013). MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene, 32(8). https://doi.org/10.1038/onc.2012.106

18.

Fantauzzo, K. A., & Soriano, P. (2015). Receptor tyrosine kinase signaling: Regulating neural crest development one phosphate at a time. In Current Topics in Developmental Biology (Vol. 111). https://doi.org/10.1016/bs.ctdb.2014.11.005

19.

Koster, J., Molenaar, J. J., & Versteeg, R. (2015, November 15). Abstract A2–45: R2: Accessible web-based genomics analysis and visualization platform for biomedical researchers. Cancer Research. American Association for Cancer Research. https://doi.org/10.1158/1538-7445.TRANSCAGEN-A2-45

20.

Kung, J. E., & Jura, N. (2019). Prospects for pharmacological targeting of pseudokinases. Nature Reviews Drug Discovery, 18(7), 501–526. https://doi.org/10.1038/s41573-019-0018-3CrossRefPubMedPubMedCentral

21.

Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., … Evans, A. E. (2009). Trk receptor expression and inhibition in neuroblastomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-08-1815

22.

Higashi, M., Sakai, K., Fumino, S., Aoi, S., Furukawa, T., & Tajiri, T. (2019). The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development. Surgery Today, 49(9), 721–727. https://doi.org/10.1007/s00595-019-01790-0CrossRefPubMed

23.

Tang, X. X., Evans, A. E., Zhao, H., Cnaan, A., London, W., Cohn, S. L., … Ikegaki, N. (1999). High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clinical Cancer Research, 5(6), 1491–1496.

24.

Tang, X. X., Zhao, H., Robinson, M. E., Cohen, B., Cnaan, A., London, W., … Ikegaki, N. (2000). Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 97(20). https://doi.org/10.1073/pnas.190123297

25.

Nozato, M., Kaneko, S., Nakagawara, A., & Komuro, H. (2013). Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma. International Journal of Oncology, 42(1), 134–140. https://doi.org/10.3892/ijo.2012.1684CrossRefPubMed

26.

Wilzén, A., Krona, C., Sveinbjörnsson, B., Kristiansson, E., Dalevi, D., Øra, I., … Abel, F. (2013). ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours. Molecular Cancer, 12(1), 1–15. https://doi.org/10.1186/1476-4598-12-70

27.

Kim, B., Van Golen, C. M., & Feldman, E. L. (2004). Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene, 23(1), 130–141. https://doi.org/10.1038/sj.onc.1206924CrossRefPubMed

28.

Van Golen, C. M., Schwab, T. S., Kim, B., Soules, M. E., Oh, S. S., Fung, K., … Feldman, E. L. (2006). Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Research, 66(13), 6570–6578. https://doi.org/10.1158/0008-5472.CAN-05-1448

29.

Pappano, W. N., Jung, P. M., Meulbroek, J. A., Wang, Y. C., Hubbard, R. D., Zhang, Q., … Wang, J. (2009). Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605. BMC Cancer, 9, 314. https://doi.org/10.1186/1471-2407-9-314

30.

Wang, X. H., Wu, H. Y., Gao, J., Wang, X. H., Gao, T. H., & Zhang, S. F. (2019). IGF1R facilitates epithelial-mesenchymal transition and cancer stem cell properties in neuroblastoma via the STAT3/AKT axis. Cancer Management and Research, 11, 5459–5472. https://doi.org/10.2147/CMAR.S196862CrossRefPubMedPubMedCentral

31.

Kurihara, S., Hakuno, F., & Takahashi, S. I. (2000). Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: The roles of MAP kinase pathway and PI 3-kinase pathway. Endocrine Journal, 47(6), 739–751. https://doi.org/10.1507/endocrj.47.739CrossRefPubMed

32.

Luberg, K., Park, R., Aleksejeva, E., & Timmusk, T. (2015). Novel transcripts reveal a complex structure of the human TRKA gene and imply the presence of multiple protein isoforms. BMC Neuroscience, 16(1). https://doi.org/10.1186/s12868-015-0215-x

33.

Reinhardt, R. R., Chin, E., Zhang, B., Roth, R. A., & Bondy, C. A. (1994). Selective coexpression of insulin receptor-related receptor (IRR) and TRK in NGF-sensitive neurons. Journal of Neuroscience, 14(8). https://doi.org/10.1523/jneurosci.14-08-04674.1994

34.

Weber, A., Huesken, C., Bergmann, E., Kiess, W., Christiansen, N. M., & Christiansen, H. (2003). Coexpression of insulin receptor-related receptor and insulin-like growth factor 1 receptor correlates with enhanced apoptosis and dedifferentiation in human neuroblastomas. Clinical Cancer Research, 9(15).

35.

Fakhari, M., Pullirsch, D., Abraham, D., Paya, K., Hofbauer, R., Holzfeind, P., … Aharinejad, S. (2002). Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer, 94(1). https://doi.org/10.1002/cncr.10177

36.

Lowery, C. D., Blosser, W., Dowless, M., Renschler, M., Perez, L. V., Stephens, J., … Falcon, B. (2019). Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget, 10(53), 5523–5533. https://doi.org/10.18632/oncotarget.27148

37.

Becker, J., Pavlakovic, H., Ludewig, F., Wilting, F., Weich, H. A., Albuquerque, R., … Wilting, J. (2010). Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clinical Cancer Research, 16(5), 1431–1441. https://doi.org/10.1158/1078-0432.CCR-09-1936

38.

Weng, W. C., Lin, K. H., Wu, P. Y., Ho, Y. H., Liu, Y. L., Wang, B. J., … Lee, H. (2017). VEGF expression correlates with neuronal differentiation and predicts a favorable prognosis in patients with neuroblastoma. Scientific Reports, 7(1), 1–11. https://doi.org/10.1038/s41598-017-11637-8

39.

Koussounadis, A., Langdon, S. P., Um, I. H., Harrison, D. J., & Smith, V. A. (2015). Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Scientific Reports 2015 5:1, 5(1), 1–9. https://doi.org/10.1038/srep10775

40.

Liu, Y., Beyer, A., & Aebersold, R. (2016). Leading edge review on the dependency of cellular protein levels on mRNA abundance. https://doi.org/10.1016/j.cell.2016.03.014

41.

DeNardo, B. D., Holloway, M. P., Ji, Q., Nguyen, K. T., Cheng, Y., Valentine, M. B., … Altura, R. A. (2013). Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS ONE, 8(12), 1–16. https://doi.org/10.1371/journal.pone.0082513

42.

Palacios-Moreno, J., Foltz, L., Guo, A., Stokes, M. P., Kuehn, E. D., George, L., … Grimes, M. L. (2015). Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts. PLoS Computational Biology, 11(4), 1–33. https://doi.org/10.1371/journal.pcbi.1004130

43.

Paratcha, G., & Ledda, F. (2008). GDNF and GFRα: A versatile molecular complex for developing neurons. Trends in Neurosciences, 31(8). https://doi.org/10.1016/j.tins.2008.05.003

44.

Ernsberger, U. (2008). The role of GDNF family ligand signalling in the differentiation of sympathetic and dorsal root ganglion neurons. Cell and Tissue Research. https://doi.org/10.1007/s00441-008-0634-4CrossRefPubMedPubMedCentral

45.

Rochette, L., Zeller, M., Cottin, Y., & Vergely, C. (2020). Insights into mechanisms of GDF15 and receptor GFRAL: Therapeutic targets. https://doi.org/10.1016/j.tem.2020.10.004

46.

De Falco, V., Carlomagno, F., Li, H., & yu, & Santoro, M. (2017). The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Practice and Research: Clinical Endocrinology and Metabolism. https://doi.org/10.1016/j.beem.2017.04.013CrossRefPubMed

47.

Takahashi, M., & Cooper, G. M. (1987). ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Molecular and Cellular Biology, 7(4). https://doi.org/10.1128/mcb.7.4.1378

48.

Ishizaka, Y., Itoh, F., Tahira, T., Ikeda, I., Ogura, T., Sugimura, T., & Nagao, M. (1989). Presence of aberrant transcripts of ret proto‐oncogene in a human papillary thyroid carcinoma cell line. Japanese Journal of Cancer Research, 80(12). https://doi.org/10.1111/j.1349-7006.1989.tb01645.x

49.

Nagao, M., Ishizaka, Y., Nakagawara, A., Kohno, K., Kuwano, M., Tahira, T., … Sugimura, T. (1990). Expression of ret proto‐oncogene in human neuroblastomas. Japanese Journal of Cancer Research, 81(4). https://doi.org/10.1111/j.1349-7006.1990.tb02566.x

50.

Iwamoto, T., Taniguchi, M., Wajjwalku, W., Nakashima, I., & Takahashi, M. (1993). Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene. British Journal of Cancer, 67(3), 504–507. https://doi.org/10.1038/bjc.1993.94CrossRefPubMedPubMedCentral

51.

Takada, N., Isogai, E., Kawamoto, T., Nakanishi, H., Todo, S., & Nakagawara, A. (2001). Retinoic acid-induced apoptosis of the CHP134 neuroblastoma cell line is associated with nuclear accumulation of p53 and is rescued by the GDNF/Ret signal. Medical And Pediatric Oncology, 36(1), 122–126. Retrieved from http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=11464863&lang=de&site=ehost-live

52.

Ishida, M., Ichihara, M., Mii, S., Jijiwa, M., Asai, N., Enomoto, A., … Takahashi, M. (2007). Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase. Cancer Science, 98(6), 815–821. https://doi.org/10.1111/j.1349-7006.2007.00457.x

53.

Futami, H., & Sakai, R. (2009). RET protein promotes non-adherent growth of NB-39-nu neuroblastoma cell line. Cancer Science, 100(6), 1034–1039. https://doi.org/10.1111/j.1349-7006.2009.01143.xCrossRefPubMed

54.

Ding, X., Xiang, L., Wang, N., Zhao, Z., Jin, X., Sun, Y., … Jin, X. (2014). Vandetanib-induced inhibition of neuroblastoma cell migration and invasion is associated with downregulation of the SDF-1/CXCR4 axis and matrix metalloproteinase 14. Oncology Reports, 31(3), 1165–1174. https://doi.org/10.3892/or.2013.2963

55.

Mabruk, Z. A., Ahmed, S. B. M., Thomas, A. C., & Prigent, S. A. (2018). The role of the ShcD and RET interaction in neuroblastoma survival and migration. Biochemistry and Biophysics Reports, 13(July 2017), 99–108. https://doi.org/10.1016/j.bbrep.2018.01.007

56.

Siaw, J. T., Gabre, J. L., Uçkun, E., Vigny, M., Zhang, W., Van den Eynden, J., … Guan, J. (2021). Loss of ret promotes mesenchymal identity in neuroblastoma cells. Cancers, 13(8). https://doi.org/10.3390/cancers13081909

57.

Cazes, A., Lopez-Delisle, L., Tsarovina, K., Pierre-Eugène, C., De Preter, K., Peuchmaur, M., … Janoueix-Lerosey, I. (2014). Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget, 5(9), 2688–2702. https://doi.org/10.18632/oncotarget.1883

58.

Lopez-Delisle, L., Pierre-Eugène, C., Louis-Brennetot, C., Surdez, D., Raynal, V., Baulande, S., … Janoueix-Lerosey, I. (2018). Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis. Oncogene, 37(11), 1417–1429. https://doi.org/10.1038/s41388-017-0039-5

59.

Zhang, L., Scorsone, K., Woodfield, S. E., & Zage, P. E. (2015). Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemotherapy and Pharmacology, 76(5), 977–987. https://doi.org/10.1007/s00280-015-2871-zCrossRefPubMed

60.

Flynn, S. M., Lesperance, J., Macias, A., Phanhthilath, N., Paul, M. R., Kim, J. W., … Zage, P. E. (2019). The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo. Oncotarget, 10(59), 6323–6333. https://doi.org/10.18632/oncotarget.27259

61.

Subramonian, D., Phanhthilath, N., Rinehardt, H., Flynn, S., Huo, Y., Zhang, J., … Zage, P. E. (2020). Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. British Journal of Cancer, 123(4), 568–579. https://doi.org/10.1038/s41416-020-0905-8

62.

Chen, Z., Zhao, Y., Yu, Y., Pang, J. C., Woodfield, S. E., Tao, L., … Yang, J. (2017). Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo. Oncotarget, 8(61), 104090–104103. https://doi.org/10.18632/oncotarget.22011

63.

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., … Garraway, L. A. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012 483:7391, 483(7391), 603–607. https://doi.org/10.1038/nature11003

64.

Ghandi, M., Huang, F. W., Jané-Valbuena, J., Kryukov, G. V., Lo, C. C., McDonald, E. R., … Sellers, W. R. (2019). Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 2019 569:7757, 569(7757), 503–508. https://doi.org/10.1038/s41586-019-1186-3

65.

Nusinow, D. P., Szpyt, J., Ghandi, M., Rose, C. M., McDonald, E. R., Kalocsay, M., … Gygi, S. P. (2020). Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell, 180(2), 387-402.e16. https://doi.org/10.1016/J.CELL.2019.12.023

66.

Bunone, G., Borrello, M. G., Picetti, R., Bongarzone, I., Peverali, F. A., De Franciscis, V., … Pierotti, M. A. (1995). Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis. Experimental Cell Research, 217(1). https://doi.org/10.1006/excr.1995.1067

67.

D’Alessio, A., De Vita, G., Cali, G., Nitsch, L., Fusco, A., Vecchio, G., … De Franciscis, V. (1995). Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. Cell Growth and Differentiation, 6(11).

68.

Peterson, S., & Bogenmann, E. (2004). The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene, 23(1), 213–225. https://doi.org/10.1038/sj.onc.1206980CrossRefPubMed

69.

Cerchia, L., D’Alessio, A., Amabile, G., Duconge, F., Pestourie, C., Tavitian, B., … De Franciscis, V. (2006). An autocrine loop involving ret and glial cell-derived neurotrophic factor mediates retinoic acid-induced neuroblastoma cell differentiation. Molecular Cancer Research, 4(7), 481–488. https://doi.org/10.1158/1541-7786.MCR-06-0050

70.

Esposito, C. L., D’Alessio, A., de Franciscis, V., & Cerchia, L. (2008). A cross-talk between TrkB and ret tyrosine kinase receptors mediates neuroblastoma cells differentiation. PLoS ONE, 3(2). https://doi.org/10.1371/journal.pone.0001643

71.

Yamada, S., Nomura, T., Uebersax, L., Matsumoto, K., Fujita, S., Miyake, M., & Miyake, J. (2007). Retinoic acid induces functional c-Ret tyrosine kinase in human neuroblastoma. NeuroReport, 18(4), 359–363. https://doi.org/10.1097/WNR.0b013e32801299b4CrossRefPubMed

72.

Lambertz, I., Kumps, C., Claeys, S., Lindner, S., Beckers, A., Janssens, E., … De Preter, K. (2015). Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: Implications for targeted treatment. Clinical Cancer Research, 21(14), 3327–3339. https://doi.org/10.1158/1078-0432.CCR-14-2024

73.

Li, Z., Xie, J., Fei, Y., Gao, P., Xie, Q., Gao, W., & Xu, Z. (2019). GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN. Biochemical and Biophysical Research Communications, 510(3). https://doi.org/10.1016/j.bbrc.2018.12.169

74.

Orentas, R. J., Khan, J., Sindiri, S., Duris, C., Wen, X., He, J., … Jarzembowski, J. (2017). Paired expression analysis of tumor cell surface antigens. Front. Oncol, 7, 173. https://doi.org/10.3389/fonc.2017.00173

75.

Tetri, L. H., Kolla, V., Golden, R. L., Iyer, R., Croucher, J. L., Choi, J. H., … Brodeur, G. M. (2020). RET receptor expression and interaction with TRK receptors in neuroblastomas. Oncology Reports, 44(1), 263–272. https://doi.org/10.3892/or.2020.7583

76.

Foltz, L., Palacios-Moreno, J., Mayfield, M., Kinch, S., Dillon, J., Syrenne, J., … Grimes, M. (2020). PAG1 directs SRC-family kinase intracellular localization to mediate receptor tyrosine kinase-induced differentiation. Molecular Biology of the Cell, 31(20). https://doi.org/10.1091/MBC.E20-02-0135

77.

Agarwal, S., Ghosh, R., Chen, Z., Lakoma, A., Gunaratne, P. H., Kim, E. S., & Shohet, J. M. (2016). Transmembrane adaptor protein PAG1 is a novel tumor suppressor in neuroblastoma. Oncotarget, 7(17), 24018. https://doi.org/10.18632/ONCOTARGET.8116

78.

Shrivastava, A., Radziejewski, C., Campbell, E., Kovac, L., McGlynn, M., Ryan, T. E., … Yancopoulos, G. D. (1997). An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Molecular Cell, 1(1). https://doi.org/10.1016/S1097-2765(00)80004-0

79.

Vogel, W., Gish, G. D., Alves, F., & Pawson, T. (1997). The discoidin domain receptor tyrosine kinases are activated by collagen. Molecular Cell, 1(1). https://doi.org/10.1016/S1097-2765(00)80003-9

80.

Vogel, W. F., Aszódi, A., Alves, F., & Pawson, T. (2001). Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Molecular and Cellular Biology, 21(8). https://doi.org/10.1128/mcb.21.8.2906-2917.2001

81.

Olaso, E., Labrador, J. P., Wang, L., Ikeda, K., Eng, F. J., Klein, R., … Friedman, S. L. (2002). Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. Journal of Biological Chemistry, 277(5). https://doi.org/10.1074/jbc.M107571200

82.

Rammal, H., Saby, C., Magnien, K., Van-Gulick, L., Garnotel, R., Buache, E., … Morjani, H. (2016). Discoidin domain receptors: Potential actors and targets in cancer. Frontiers in Pharmacology, 7(MAR), 1–13. https://doi.org/10.3389/fphar.2016.00055

83.

Henriet, E., Sala, M., Abou Hammoud, A., Tuariihionoa, A., Di Martino, J., Ros, M., & Saltel, F. (2018). Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer. Cell Adhesion and Migration, 12(4), 363–377. https://doi.org/10.1080/19336918.2018.1465156CrossRefPubMedPubMedCentral

84.

Chander, V. M. H., & Munshi, A. (2021). Complex roles of discoidin domain receptor tyrosine kinases in cancer. Clinical and Translational Oncology, (0123456789). https://doi.org/10.1007/s12094-021-02552-6

85.

Ford, C. E., Lau, S. K., Zhu, C. Q., Andersson, T., Tsao, M. S., & Vogel, W. F. (2007). Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. British Journal of Cancer, 96(5). https://doi.org/10.1038/sj.bjc.6603614

86.

Hammerman, P. S., Sos, M. L., Ramos, A. H., Xu, C., Dutt, A., Zhou, W., … Meyerson, M. (2011). Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery, 1(1). https://doi.org/10.1158/2159-8274.CD-11-0005

87.

Beauchamp, E. M., Woods, B. A., Dulak, A. M., Tan, L., Xu, C., Gray, N. S., … Hammerman, P. S. (2014). Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Molecular Cancer Therapeutics, 13(2). https://doi.org/10.1158/1535-7163.MCT-13-0817

88.

Wang, J., Li, L., Liu, S., Zhao, Y., Wang, L., & Du, G. (2016). FOXC1 promotes melanoma by activating MST1R/PI3K/AKT pathway and is associated with poor prognosis in melanoma. Oncotarget, 7(51), 84375–84387. https://doi.org/10.18632/oncotarget.11224

89.

Van Groningen, T., Koster, J., Valentijn, L. J., Zwijnenburg, D. A., Akogul, N., Hasselt, N. E., … Versteeg, R. (2017). Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nature Genetics, 49(8), 1261–1266. https://doi.org/10.1038/ng.3899

90.

Bildsoe, H., Fan, X., Wilkie, E. E., Ashoti, A., Jones, V. J., Power, M., … Loebel, D. A. F. (2016). Transcriptional targets of TWIST1 in the cranial mesoderm regulate cell-matrix interactions and mesenchyme maintenance. Developmental Biology, 418(1), 189–203. https://doi.org/10.1016/j.ydbio.2016.08.016

91.

Grither, W. R., Divine, L. M., Meller, E. H., Wilke, D. J., Desai, R. A., Loza, A. J., … Fuh, K. C. (2018). TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis. Oncogene, 37(13), 1714–1729. https://doi.org/10.1038/s41388-017-0043-9

92.

Zhu, Q. Q., Ma, C., Wang, Q., Song, Y., & Lv, T. (2016). The role of TWIST1 in epithelial-mesenchymal transition and cancers. Tumor Biology, 37(1), 185–197. https://doi.org/10.1007/s13277-015-4450-7CrossRefPubMed

93.

Zhang, K., Corsa, C. A., Ponik, S. M., Prior, J. L., Piwnica-Worms, D., Eliceiri, K. W., … Longmore, G. D. (2013). The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nature Cell Biology, 15(6). https://doi.org/10.1038/ncb2743

94.

Selmi, A., de Saint-Jean, M., Jallas, A. C., Garin, E., Hogarty, M. D., Bénard, J., … Valsesia-Wittmann, S. (2015). TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Letters, 357(1), 412–418. https://doi.org/10.1016/j.canlet.2014.11.056

95.

Orr-Urtreger, A., Bedford, M. T., Do, M. S., Eisenbach, L., & Lonai, P. (1992). Developmental expression of the α receptor for platelet-derived growth factor, which is deleted in the embryonic lethal Patch mutation. Development, 115(1).

96.

Olson, L. E., & Soriano, P. (2009). Increased PDGFRα activation disrupts connective tissue development and drives systemic fibrosis. Developmental Cell, 16(2). https://doi.org/10.1016/j.devcel.2008.12.003

97.

Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., Von Mehren, M., Joensuu, H., … Fletcher, J. A. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology, 21(23). https://doi.org/10.1200/JCO.2003.04.190

98.

Heldin, C. H., Lennartsson, J., & Westermark, B. (2018). Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. Journal of Internal Medicine, 283(1), 16–44. https://doi.org/10.1111/joim.12690CrossRefPubMed

99.

Zanelli, M., Smith, M., Zizzo, M., Carloni, A., Valli, R., De Marco, L., … Ascani, S. (2019). A tricky and rare cause of pulmonary eosinophilia: Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA. BMC Pulmonary Medicine, 19(1). https://doi.org/10.1186/s12890-019-0967-7

100.

Smith, J. S., Wang, X. Y., Qian, J., Hosek, S. M., Scheithauer, B. W., Jenkins, R. B., & James, C. D. (2000). Amplification of the platelet-derived growth factor receptor-a (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. Journal of Neuropathology and Experimental Neurology, 59(6), 495–503. https://doi.org/10.1093/jnen/59.6.495CrossRefPubMed

101.

Arai, H., Ueno, T., Tangoku, A., Yoshino, S., Abe, T., Kawauchi, S., … Sasaki, K. (2003). Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: Comparison with conventional comparative genomic hybridization analysis. Cancer Genetics and Cytogenetics, 146(1), 16–21. https://doi.org/10.1016/S0165-4608(03)00106-7

102.

Zhao, J., Roth, J., Bode-Lesniewska, B., Pfaltz, M., Heitz, P. U., & Komminoth, P. (2002). Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes and Cancer, 34(1), 48–57. https://doi.org/10.1002/gcc.10035CrossRefPubMed

103.

Matsui, T., Sano, K., Tsukamoto, T., Ito, M., Takaishi, T., Nakata, H., … Chihara, K. (1993). Human neuroblastoma cells express α and β platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. Journal of Clinical Investigation, 92(3), 1153–1160. https://doi.org/10.1172/JCI116684

104.

Beppu, K., Jaboine, J., Merchant, M. S., Mackall, C. L., & Thiele, C. J. (2004). Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. Journal of the National Cancer Institute, 96(1), 46–55. https://doi.org/10.1093/jnci/djh004CrossRefPubMed

105.

Mei, Y., Wang, Z., Zhang, L., Zhang, Y., Li, X., Liu, H., … You, H. (2012). Regulation of neuroblastoma differentiation by forkhead transcription factors FOXO1/3/4 through the receptor tyrosine kinase PDGFRA. Proceedings of the National Academy of Sciences of the United States of America, 109(13), 4898–4903. https://doi.org/10.1073/pnas.1119535109

106.

Hutt, K. J., McLaughlin, E. A., & Holland, M. K. (2006). KIT/KIT ligand in mammalian oogenesis and folliculogenesis: Roles in rabbit and murine ovarian follicle activation and oocyte growth. Biology of Reproduction, 75(3), 421–433. https://doi.org/10.1095/biolreprod.106.051516CrossRefPubMed

107.

Luo, R., Gao, J., Wehrle-Haller, B., & Henion, P. D. (2003). Molecular identification of distinct neurogenic and melanogenic neural crest sublineages. Development, 130(2), 321–330. https://doi.org/10.1242/dev.00213CrossRefPubMed

108.

Babaei, M. A., Kamalidehghan, B., Saleem, M., Huri, H. Z., & Ahmadipour, F. (2016). Receptor tyrosine kinase (c-Kit) inhibitors: A potential therapeutic target in cancer cells. Drug Design, Development and Therapy, 10, 2443–2459. https://doi.org/10.2147/DDDT.S89114CrossRef

109.

Korja, M., Finne, J., Salmi, T. T., Haapasalo, H., Tanner, M., & Isola, J. (2005). No GIST-type c-kit gain of function mutations in neuroblastic tumours. Journal of Clinical Pathology, 58(7), 762–765. https://doi.org/10.1136/jcp.2004.024331CrossRefPubMedPubMedCentral

110.

Cohen, P. S., Chan, J. P., Lipkunskaya, M., Biedler, J. L., & Seeger, R. C. (1994). Expression of stem cell factor and c-kit in human neuroblastoma. Blood, 84(10), 3465–3472. https://doi.org/10.1182/blood.v84.10.3465.3465CrossRefPubMed

111.

Beck, D., Gross, N., Brognara, C., & Perruisseau, G. (1995). Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors. Blood, 86(8). https://doi.org/10.1182/blood.v86.8.3132.bloodjournal8683132

112.

Smithey, B. E., Pappo, A. S., & Hill, D. A. (2002). c-kit expression in pediatric solid tumors: A comparative immunohistochemical study. American Journal of Surgical Pathology, 26(4). https://doi.org/10.1097/00000478-200204000-00011

113.

Jögi, A., Øra, I., Nilsson, H., Lindeheim, Å., Makino, Y., Poellinger, L., … Påhlman, S. (2002). Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proceedings of the National Academy of Sciences of the United States of America, 99(10), 7021–7026. https://doi.org/10.1073/pnas.102660199

114.

Vitali, R., Cesi, V., Nicotra, M. R., McDowell, H. P., Donfrancesco, A., Mannarino, O., … Dominici, C. (2003). c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. International Journal of Cancer, 106(2), 147–152. https://doi.org/10.1002/ijc.11187

115.

Uccini, S., Mannarino, O., McDowell, H. P., Pauser, U., Vitali, R., Natali, P. G., … Dominici, C. (2005). Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. Clinical Cancer Research, 11(1), 380–389.

116.

Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., … Brenner, M. K. (2004). A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 101(39), 14228–14233. https://doi.org/10.1073/pnas.0400067101

117.

Lau, S. T., Hansford, L. M., Chan, W. K., Chan, G. C. F., Wan, T. S. K., Wong, K. K. Y., … Ngan, E. S. W. (2015). Prokineticin signaling is required for the maintenance of a de novo population of c-KIT+ cells to sustain neuroblastoma progression. Oncogene, 34(8), 1019–1034. https://doi.org/10.1038/onc.2014.24

118.

Krams, M., Parwaresch, R., Sipos, B., Heidorn, K., Harms, D., & Rudolph, P. (2004). Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene, 23(2), 588–595. https://doi.org/10.1038/sj.onc.1207145CrossRefPubMed

119.

Shimada, A., Hirato, J., Kuroiwa, M., Kikuchi, A., Hanada, R., Wakai, K., & Hayashi, Y. (2008). Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma. Pediatric Blood and Cancer, 50(2). https://doi.org/10.1002/pbc.21288

120.

Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., De Pontual, L., Combaret, V., … Delattre, O. (2008). Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 455(7215). https://doi.org/10.1038/nature07398

121.

Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., … Ogawa, S. (2008). Oncogenic mutations of ALK kinase in neuroblastoma. Nature, 455(7215). https://doi.org/10.1038/nature07399

122.

Carén, H., Abel, F., Kogner, P., & Martinsson, T. (2008). High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochemical Journal, 416(2). https://doi.org/10.1042/BJ20081834

123.

Trigg, R. M., & Turner, S. D. (2018). ALK in neuroblastoma: Biological and therapeutic implications. Cancers, 10(4). https://doi.org/10.3390/cancers10040113

124.

Janoueix-Lerosey, I., Lopez-Delisle, L., Delattre, O., & Rohrer, H. (2018). The ALK receptor in sympathetic neuron development and neuroblastoma. Cell and Tissue Research, 372(2), 325–337. https://doi.org/10.1007/s00441-017-2784-8CrossRefPubMed

125.

Umapathy, G., Mendoza-Garcia, P., Hallberg, B., & Palmer, R. H. (2019). Targeting anaplastic lymphoma kinase in neuroblastoma. APMIS, 127(5), 288–302. https://doi.org/10.1111/apm.12940CrossRefPubMedPubMedCentral

126.

Yoshikawa, S., McKinnon, R. D., Kokel, M., & Thomas, J. B. (2003). Wnt-mediated axon guidance via the Drosophila derailed receptor. Nature, 422(6932). https://doi.org/10.1038/nature01522

127.

Peradziryi, H., Kaplan, N. A., Podleschny, M., Liu, X., Wehner, P., Borchers, A., & Tolwinski, N. S. (2011). PTK7/Otk interacts with Wnts and inhibits canonical Wnt signalling. EMBO Journal, 30(18). https://doi.org/10.1038/emboj.2011.236

128.

Jing, L., Lefebvre, J. L., Gordon, L. R., & Granato, M. (2009). Wnt signals organize synaptic prepattern and axon guidance through the zebrafish unplugged/MuSK receptor. Neuron, 61(5). https://doi.org/10.1016/j.neuron.2008.12.025

129.

Oishi, I., Suzuki, H., Onishi, N., Takada, R., Kani, S., Ohkawara, B., … Minami, Y. (2003). The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes to Cells, 8(7). https://doi.org/10.1046/j.1365-2443.2003.00662.x

130.

Green, J., Nusse, R., & van Amerongen, R. (2014). The role of Ryk and Ror receptor tyrosine kinases in wnt signal transduction. Cold Spring Harbor Perspectives in Biology, 6(2), 1–12. https://doi.org/10.1101/cshperspect.a009175CrossRef

131.

Debebe, Z., & Rathmell, W. K. (2015). Ror2 as a therapeutic target in cancer. Pharmacology and Therapeutics, 150, 143–148. https://doi.org/10.1016/j.pharmthera.2015.01.010CrossRefPubMed

132.

Oconnell, M. P., Fiori, J. L., Xu, M., Carter, A. D., Frank, B. P., Camilli, T. C., … Weeraratna, A. T. (2010). The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene, 29(1). https://doi.org/10.1038/onc.2009.305

133.

Rasmussen, N. R., Debebe, Z., Wright, T. M., Brooks, S. A., Sendor, A. B., Brannon, A. R., … Rathmell, W. K. (2014). Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. PLoS ONE, 9(12). https://doi.org/10.1371/journal.pone.0116101

134.

Xu, Y., Ma, Y. H., Pang, Y. X., Zhao, Z., Lu, J. J., Mao, H. L., & Liu, P. S. (2017). Ectopic repression of receptor tyrosine kinase-like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial-mesenchymal transition. Tumor Biology, 39(5). https://doi.org/10.1177/1010428317701627

135.

Roarty, K., Pfefferle, A. D., Creighton, C. J., Perou, C. M., & Rosen, J. M. (2017). Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene, 36(43). https://doi.org/10.1038/onc.2017.206

136.

Fu, Y., Chen, Y., Huang, J., Cai, Z., & Wang, Y. (2020). RYK, a receptor of noncanonical Wnt ligand Wnt5a, is positively correlated with gastric cancer tumorigenesis and potential of liver metastasis. American Journal of Physiology - Gastrointestinal and Liver Physiology, 318(2), G352–G360. https://doi.org/10.1152/AJPGI.00228.2019CrossRefPubMed

137.

Katso, R. M. T., Manek, S., Biddolph, S., Whittaker, R., Charnock, M. F. L., Wells, M., & Ganesan, T. S. (1999). Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: Correlation with up-regulation in epithelial ovarian cancer. Cancer Research, 59(10).

138.

Ji, Y., Hao, H., Reynolds, K., Mcmahon, M., & Zhou, C. J. (2019). cells Wnt signaling in neural crest ontogenesis and oncogenesis. https://doi.org/10.3390/cells8101173

139.

Becker, J., & Wilting, J. (2019). Wnt signaling in neuroblastoma. Cancers, 11(7). https://doi.org/10.3390/cancers11071013

140.

Becker, J., & Wilting, J. (2018). WNT signaling, the development of the sympathoadrenal–paraganglionic system and neuroblastoma. Cellular and Molecular Life Sciences, 75(6), 1057–1070. https://doi.org/10.1007/s00018-017-2685-8CrossRefPubMed

141.

Masiakowski, P., & Carroll, R. D. (1992). A novel family of cell surface receptors with tyrosine kinase-like domain. Journal of Biological Chemistry, 267(36). https://doi.org/10.1016/s0021-9258(18)35733-8

142.

Podleschny, M., Grund, A., Berger, H., Rollwitz, E., & Borchers, A. (2015). A PTK7/Ror2 co-receptor complex affects xenopus neural crest migration. PLoS ONE, 10(12), 1–19. https://doi.org/10.1371/journal.pone.0145169CrossRef

143.

Dave, H., Butcher, D., Anver, M., & Bollard, C. M. (2019). ROR1 and ROR2—Novel targets for neuroblastoma. Pediatric Hematology and Oncology, 36(6). https://doi.org/10.1080/08880018.2019.1646365

144.

Hernandez Tejada, F. N., Najjar, A., Guerrero, A. D., Flores, L. G., & Singh, H. (2018). ROR1-specific CAR for neuroblastoma using sleeping beauty -modified t cells. . Journal of Clinical Oncology, 36(15_suppl). https://doi.org/10.1200/jco.2018.36.15_suppl.10523

145.

Illendula, A., Fultang, N., & Peethambaran, B. (2020). Retinoic acid induces differentiation in neuroblastoma via ROR1 by modulating retinoic acid response elements. Oncology Reports, 44(3), 1013–1024. https://doi.org/10.3892/or.2020.7681CrossRefPubMedPubMedCentral

146.

Malik, R., Mambetsariev, I., Fricke, J., Chawla, N., Nam, A., Pharaon, R., & Salgia, R. (2020). MET receptor in oncology: From biomarker to therapeutic target. In Advances in Cancer Research (Vol. 147). https://doi.org/10.1016/bs.acr.2020.04.006

147.

Ichimura, E., Maeshima, A., Nakajima, T., & Nakamura, T. (1996). Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Japanese Journal of Cancer Research, 87(10). https://doi.org/10.1111/j.1349-7006.1996.tb03111.x

148.

Lee, J., Ou, S. H. I., Lee, J. M., Kim, H. C., Hong, M., Kim, S. Y., … Kim, K. M. (2015). Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget, 6(29). https://doi.org/10.18632/oncotarget.4721

149.

Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013). Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-12-2791CrossRefPubMedPubMedCentral

150.

Takayama, H., LaRochelle, W. J., Anver, M., Bockman, D. E., & Merlino, G. (1996). Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proceedings of the National Academy of Sciences of the United States of America, 93(12), 5866–5871. https://doi.org/10.1073/pnas.93.12.5866CrossRefPubMedPubMedCentral

151.

Hecht, M., Papoutsi, M., Tran, H. D., Wilting, J., & Schweigerer, L. (2004). Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Research, 64(17), 6109–6118. https://doi.org/10.1158/0008-5472.CAN-04-1014CrossRefPubMed

152.

Hecht, M., Schulte, J. H., Eggert, A., Wilting, J., & Schweigerer, L. (2005). The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. Carcinogenesis, 26(12), 2105–2115. https://doi.org/10.1093/carcin/bgi192CrossRefPubMed

153.

Schweigerer, L., Rave-Fränk, M., Schmidberger, H., & Hecht, M. (2005). Sublethal irradiation promotes invasiveness of neuroblastoma cells. Biochemical and Biophysical Research Communications, 330(3), 982–988. https://doi.org/10.1016/j.bbrc.2005.03.068CrossRefPubMed

154.

Yan, B., Lim, M., Zhou, L., Kuick, C. H., Leong, M. Y., Yong, K. J., … Chang, K. T. E. (2013). Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas. Journal of Clinical Pathology, 66(11), 985–991. https://doi.org/10.1136/jclinpath-2012-201375

155.

Crosswell, H. E., Dasgupta, A., Alvarado, C. S., Watt, T., Christensen, J. G., De, P., … Findley, H. W. (2009). PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer, 9, 1–10. https://doi.org/10.1186/1471-2407-9-411

156.

Scorsone, K., Zhang, L., Woodfield, S. E., Hicks, J., & Zage, P. E. (2014). The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Investigational New Drugs, 32(5), 815–824. https://doi.org/10.1007/s10637-014-0107-4CrossRefPubMed

157.

Jahangiri, A., De Lay, M., Miller, L. M., Shawn Carbonell, W., Hu, Y. L., Lu, K., … Aghi, M. K. (2013). Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clinical Cancer Research, 19(7), 1773–1783. https://doi.org/10.1158/1078-0432.CCR-12-1281

158.

Daudigeos-Dubus, E., Le Dret, L., Bawa, O., Opolon, P., Vievard, A., Villa, I., … Geoerger, B. (2017). Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. International Journal of Oncology, 50(1), 203–211. https://doi.org/10.3892/ijo.2016.3792

159.

Ishiwata, T. (2018). Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Frontiers in Bioscience - Landmark, 23(4). https://doi.org/10.2741/4609

160.

Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., … Goldfarb, M. (1996). Receptor specificity of the fibroblast growth factor family. Journal of Biological Chemistry, 271(25). https://doi.org/10.1074/jbc.271.25.15292

161.

Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., & Ornitz, D. M. (2006). Receptor specificity of the fibroblast growth factor family: The complete mammalian FGF family. Journal of Biological Chemistry, 281(23). https://doi.org/10.1074/jbc.M601252200

162.

De Moerlooze, L., Spencer-Dene, B., Revest, J. M., Hajihosseini, M., Rosewell, I., & Dickson, C. (2000). An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development, 127(3). https://doi.org/10.1042/cs099005p

163.

Revest, J. M., Spencer-Dene, B., Kerr, K., De Moerlooze, L., Rosewell, I., & Dickson, C. (2001). Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. Developmental Biology, 231(1). https://doi.org/10.1006/dbio.2000.0144

164.

Hierro, C., Alsina, M., Sánchez, M., Serra, V., Rodon, J., & Tabernero, J. (2017). Targeting the fibroblast growth factor receptor 2 in gastric cancer: Promise or pitfall? Annals of Oncology. https://doi.org/10.1093/annonc/mdx081CrossRefPubMed

165.

Li, L., Zhang, S., Wei, L., Wang, Z., Ma, W., Liu, F., & Qian, Y. (2018). FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer. Oncology Letters, 16(2). https://doi.org/10.3892/ol.2018.8903

166.

Fernández-Nogueira, P., Mancino, M., Fuster, G., López-Plana, A., Jauregui, P., Almendro, V., … Bragado, P. (2020). Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. Clinical Cancer Research, 26(6). https://doi.org/10.1158/1078-0432.CCR-19-0353

167.

Tyulyandina, A., Harrison, D., Yin, W., Stepanova, E., Kochenkov, D., Solomko, E., … Tsimafeyeu, I. (2017). Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies. Investigational New Drugs, 35(2). https://doi.org/10.1007/s10637-016-0404-1

168.

Stehbens, S. J., Ju, R. J., Adams, M. N., Perry, S. R., Haass, N. K., Bryant, D. M., & Pollock, P. M. (2018). FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models. Journal of Cell Science, 131(15). https://doi.org/10.1242/jcs.213678

169.

Mahipal, A., Tella, S. H., Kommalapati, A., Anaya, D., & Kim, R. (2019). FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2019.06.003CrossRefPubMed

170.

Fults, D., Pedone, C. A., Thompson, G. E., Uchiyama, C. M., Gumpper, K. L., Iliev, D., … Perry, W. L. (1998). Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. International Journal of Oncology, 12(4). https://doi.org/10.3892/ijo.12.4.905

171.

Healy, E., Belgaid, C., Takata, M., Harrison, D., Zhu, N. W., Burd, D. A. R., … Rees, J. L. (1998). Prognostic significance of allelic losses in primary melanoma. Oncogene, 16(17). https://doi.org/10.1038/sj.onc.1200203

172.

Trybus, T. M., Burgess, A. C., Wojno, K. J., Glover, T. W., & Macoska, J. A. (1996). Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Research, 56(10).

173.

Altura, R. A., Maris, J. H., Li, H., Boyett, J. M., Brodeur, G. M., & Look, A. T. (1997). Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. Genes Chromosomes and Cancer, 19(3), 176–184. https://doi.org/10.1002/(SICI)1098-2264(199707)19:3%3c176::AID-GCC7%3e3.0.CO;2-VCrossRefPubMed

174.

Lázcoz, P., Muñoz, J., Nistal, M., Pestaña, Á., Encío, I. J., & Castresana, J. S. (2007). Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genetics and Cytogenetics, 174(1), 1–8. https://doi.org/10.1016/j.cancergencyto.2006.08.014CrossRefPubMed

175.

Salm, F., Cwiek, P., Ghosal, A., Lucia Buccarello, A., Largey, F., Wotzkow, C., … Arcaro, A. (2013). RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. Oncogene, 32(34), 3944–3953. https://doi.org/10.1038/onc.2012.416

176.

Emdal, K. B., Pedersen, A. K., Bekker-Jensen, D. B., Lundby, A., Claeys, S., De Preter, K., … Olsen, J. V. (2018). Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Science Signaling, 11(557). https://doi.org/10.1126/SCISIGNAL.AAP9752/FORMAT/PDF/OEBPS/PAGES/1.PAGE.XHTML

177.

Van Den Eynden, J., Umapathy, G., Ashouri, A., Cervantes-Madrid, D., Szydzik, J., Ruuth, K., … Hallberg, B. (2018). Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways. Science Signaling, 11(557). https://doi.org/10.1126/SCISIGNAL.AAR5680

178.

Braekeveldt, N., Von Stedingk, K., Fransson, S., Martinez-Monleon, A., Lindgren, D., Axelson, H., … Bexell, D. (2018). Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma. Cancer Research, 78(20). https://doi.org/10.1158/0008-5472.CAN-18-0527

Title: Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology
Authors: Esteban Javier Rozen
Jason Matthew Shohet
Publication date: 01-03-2022
Publisher: Springer US
Keywords: Neuroblastoma
Neuroblastoma
Published in: Cancer and Metastasis Reviews / Issue 1/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-021-10001-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Lipid metabolism reprogramming in renal cell carcinoma

Glioma: molecular signature and crossroads with tumor microenvironment

Glycosylation as a regulator of site-specific metastasis

COVID-19 and cancer: start the resolution!

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer